on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its position in Avadel Pharmaceuticals plc through a Form 8.3 submission under the Irish Takeover Panel rules. On December 3, 2025, Vanguard reported holding 5,577,794 ordinary shares, representing a 5.73% stake in Avadel.
The filing reveals transactions involving US$0.01 ordinary shares, including a purchase of 132 shares at $21.36 each. Additionally, sales include 2,419 shares at $21.36 and 2,342 shares at $21.37.
No cash-settled or stock-settled derivatives activities were reported, and there were no indemnity or option arrangements in place relating to Avadel securities.
This disclosure is in accordance with the Irish Takeover Panel Act, 1997, reflecting transparency requirements for parties holding significant interests in relevant securities.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news